NeuroDerm

About:

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system

Top Investors: Robert Taub, The Elias Group

Description:

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

Total Funding Amount:

$171M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Rehovot, HaMerkaz, Israel

Founded Date:

2003-01-01

Founders:

Eli Heldman

Number of Employees:

101-250

Last Funding Date:

2016-12-07

IPO Status:

Delisted

Industries: